111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection
- 1 December 2016
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (12) , 818-826
Abstract
No abstract availableKeywords
Funding Information
- Canadian Breast Cancer Foundation, Ontario Region
- Canadian Institutes of Health Research
- U.S. Department of Defense Breast Cancer Research Program
- Terry Fox Foundation
This publication has 24 references indexed in Scilit:
- Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast CancerJournal of Nuclear Medicine, 2016
- Evaluation of uptake and distribution of gold nanoparticles in solid tumorsThe European Physical Journal Plus, 2015
- Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, 177LuMolecular Pharmaceutics, 2015
- Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiationBreast Cancer Research and Treatment, 2012
- Role of Antibody-Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in VivoMolecular Pharmaceutics, 2012
- Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancerChemical Society Reviews, 2011
- Design and Characterization of HER-2-Targeted Gold Nanoparticles for Enhanced X-radiation Treatment of Locally Advanced Breast CancerMolecular Pharmaceutics, 2010
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast CancerJournal of Nuclear Medicine, 2007
- Primary Chemotherapy in Breast CancerAmerican Journal of Clinical Oncology, 1998